BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 6651397)

  • 1. First results on the effects of MAO inhibition on cognitive functioning in elderly depressed patients.
    Georgotas A; Reisberg B; Ferris S
    Arch Gerontol Geriatr; 1983 Nov; 2(3):249-54. PubMed ID: 6651397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistant geriatric depressions and therapeutic response to monoamine oxidase inhibitors.
    Georgotas A; Friedman E; McCarthy M; Mann J; Krakowski M; Siegel R; Ferris S
    Biol Psychiatry; 1983 Feb; 18(2):195-205. PubMed ID: 6830930
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of atypical depression with cognitive therapy or phenelzine: a double-blind, placebo-controlled trial.
    Jarrett RB; Schaffer M; McIntire D; Witt-Browder A; Kraft D; Risser RC
    Arch Gen Psychiatry; 1999 May; 56(5):431-7. PubMed ID: 10232298
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of psychotic and nonpsychotic depression to phenelzine.
    Janicak PG; Pandey GN; Davis JM; Boshes R; Bresnahan D; Sharma R
    Am J Psychiatry; 1988 Jan; 145(1):93-5. PubMed ID: 3337297
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Monoamine oxidase inhibitors phenelzine and brofaromine increase plasma serotonin and decrease 5-hydroxyindoleacetic acid in patients with major depression: relationship to clinical improvement.
    Celada P; Pérez J; Alvarez E; Artigas F
    J Clin Psychopharmacol; 1992 Oct; 12(5):309-15. PubMed ID: 1282522
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of response to nortriptyline and phenelzine by platelet MAO activity.
    Georgotas A; McCue RE; Friedman E; Cooper T
    Am J Psychiatry; 1987 Mar; 144(3):338-40. PubMed ID: 3826434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treating DSM-IV depression with atypical features.
    Stewart JW; Thase ME
    J Clin Psychiatry; 2007 Apr; 68(4):e10. PubMed ID: 17474800
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pretreatment dexamethasone suppression test as a predictor of response to phenelzine.
    Janicak PG; Pandey GN; Sharma R; Boshes R; Bresnahan D; Davis JM
    J Clin Psychiatry; 1987 Dec; 48(12):480-2. PubMed ID: 3693333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.
    Rosenzweig P; Patat A; Zieleniuk I; Cimarosti I; Allain H; Gandon JM
    Clin Pharmacol Ther; 1998 Aug; 64(2):211-22. PubMed ID: 9728902
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MAO inhibition and clinical response in depressed patients treated with phenelzine.
    Bresnahan DB; Pandey GN; Janicak PG; Sharma R; Boshes RA; Chang SS; Gierl BL; Davis JM
    J Clin Psychiatry; 1990 Feb; 51(2):47-50. PubMed ID: 2298705
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phenelzine treatment of melancholia.
    McGrath PJ; Stewart JW; Harrison W; Wager S; Quitkin FM
    J Clin Psychiatry; 1986 Aug; 47(8):420-2. PubMed ID: 3525522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and tolerability of tranylcypromine versus phenelzine: a double-blind study in antidepressant-refractory depressed inpatients.
    Birkenhäger TK; van den Broek WW; Mulder PG; Bruijn JA; Moleman P
    J Clin Psychiatry; 2004 Nov; 65(11):1505-10. PubMed ID: 15554763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between response to phenelzine and MAO inhibition in a clinical trial of phenelzine, amitriptyline and placebo.
    Raft D; Davidson J; Wasik J; Mattox A
    Neuropsychobiology; 1981; 7(3):122-6. PubMed ID: 7231652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MAOIs in the contemporary treatment of depression.
    Thase ME; Trivedi MH; Rush AJ
    Neuropsychopharmacology; 1995 May; 12(3):185-219. PubMed ID: 7612154
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phenelzine for chronic depression: a study of continuation treatment.
    Harrison W; Rabkin J; Stewart JW; McGrath PJ; Tricamo E; Quitkin F
    J Clin Psychiatry; 1986 Jul; 47(7):346-9. PubMed ID: 3522558
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies.
    Chouinard G; Saxena BM; Nair NP; Kutcher SP; Bakish D; Bradwejn J; Kennedy SH; Sharma V; Remick RA; Kukha-Mohamad SA
    Clin Neuropharmacol; 1993; 16 Suppl 2():S51-4. PubMed ID: 8313397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment response of depressed outpatients unresponsive to both a tricyclic and a monoamine oxidase inhibitor antidepressant.
    McGrath PJ; Stewart JW; Nunes EN; Quitkin FM
    J Clin Psychiatry; 1994 Aug; 55(8):336-9. PubMed ID: 8071301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desipramine versus phenelzine in recurrent unipolar depression: clinical characteristics and treatment response.
    Swann AC; Bowden CL; Rush AJ; Rhoades H; Rose R; Kobes R
    J Clin Psychopharmacol; 1997 Apr; 17(2):78-83. PubMed ID: 10950467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential response patterns to MAO inhibitors and tricyclics.
    Nies A
    J Clin Psychiatry; 1984 Jul; 45(7 Pt 2):70-7. PubMed ID: 6376487
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination monoamine oxidase inhibitor and beta-blocker treatment of migraine, with anxiety and depression.
    Merikangas KR; Merikangas JR
    Biol Psychiatry; 1995 Nov; 38(9):603-10. PubMed ID: 8573662
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.